Tag Archives: Booster doses

EU agency says omicron pushing COVID-19 out of pandemic phase

An official from Europe’s top medical product regulation agency said Tuesday that the COVID-19 omicron variant may be pushing the pandemic into becoming endemic.

Marco Cavaleri, head of vaccine strategy for the European Medicines Agency (EMA), told reporters on Tuesday that that the natural immunity conferred by the highly-infectious omicron strain may be fast-tracking the progress towards endemicity.

“With the increase of immunity in population – and with Omicron, there will be a lot of natural immunity taking place on top of vaccination – we will be fast moving towards a scenario that will be closer to endemicity,” Cavaleri said during a media briefing, according to Al Jazeera.

When a virus becomes endemic it means a population has gained enough widespread immunity — either from infection or vaccination — that transmissions, hospitalizations and deaths will start to go down.

Reports from South Africa, where omicron was first detected, have indicated that while the variant is highly-infectious, it does not result in a corresponding spike in hospitalizations and deaths. Another South African study released last month found that omicron may reduce infections caused by the delta variant by building cross-immunity to different strains, an effect that has not been observed in many other mutations of the SARS-CoV-2 virus.

During his briefing on Tuesday, Reuters reported that Cavaleri also expressed doubts about the necessity for a fourth COVID-19 vaccine dose, telling the reporters that such an approach was not “sustainable.”

“While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy,” he said.

“It is important that there is a good discussion around the choice of the composition of the vaccine to make sure that we have a strategy that is not just reactive … and try to come up with an approach that will be suitable in order to prevent a future variant,” he added.

Cavaleri’s remarks echo those of British infectious disease expert Sir Andrew Pollard who said earlier this month that repeated vaccination every few months was “not sustainable.”

Pollard, who helped to develop the AstraZeneca COVID-19 vaccine, said, “It really is not affordable, sustainable or probably even needed to vaccinate everyone on the planet every four to six months.”

“We haven’t even managed to vaccinate everyone in Africa with one dose so we’re certainly not going to get to a point where fourth doses for everyone is manageable,” he added.



Read original article here

Study suggests antibodies from two Moderna doses less effective at neutralizing omicron

A preprint study published Wednesday indicated that the antibodies in blood samples from recipients of two Moderna doses were less effective at neutralizing the omicron variant, suggesting an increased risk of symptomatic breakthrough cases. 

The preliminary research, which has not yet been peer-reviewed, analyzed blood samples from 30 participants fully vaccinated with two Moderna doses. Researchers tested antibodies in the blood with “pseudovirus” versions of the omicron strain at National Institutes of Health and Duke University laboratories.

They found these antibodies in two-dose Moderna recipients were at least 50 times less effective at neutralizing the omicron strain, which “could lead to an increased risk of symptomatic breakthrough infections.”

But the seven participants who received a Moderna booster saw an about 12-fold improvement in the neutralization against the omicron variant, which researchers noted “may substantially reduce the risk” of COVID-19.

Data from South Africa also found that two doses of the Pfizer-BioNTech vaccine were only 33 percent effective at preventing omicron infection, although it was still 70 percent effective against hospitalization. 

Top infectious disease expert Anthony FauciAnthony FauciPoll: 71 percent support Biden’s omicron travel ban Kate McKinnon reprises Fauci role on ‘Saturday Night Live’ with holiday pandemic tips Sunday shows – Spotlight shifts to deadly storms MORE cited the preliminary data on the effectiveness of mRNA boosters when saying there’s no need for a vaccine designed specifically to combat the omicron variant yet.

“Our booster vaccine regimens work against omicron,” Fauci said at a Wednesday briefing. “At this point there is no need for a variant-specific booster.”

Slightly more than a quarter of the U.S. population has received their booster dose, according to Centers for Disease Control and Prevention (CDC) data.

Fauci said the Moderna preprint study on the Moderna vaccine will be published in a preprint server “next week.”

Scientists raised concerns about the omicron variant first reported in South Africa and Botswana in late November due to its high number of mutations, and early data indicates it’s more transmissible than the delta variant and doubling every two days.

At least 36 states and 75 countries have identified omicron cases. The CDC estimates that the strain makes up 3 percent of cases in the U.S., with higher rates in areas like New York and New Jersey.

“Looking at early data on transmissibility of omicron from other countries, we expect to see the proportion of omicron cases here in the United States continue to grow in the coming weeks,” CDC Director Rochelle WalenskyRochelle WalenskyBiden marks 800K COVID-19 deaths by urging Americans to get vaccinated CDC estimates omicron now 3 percent of US COVID-19 cases The Hill’s Morning Report – Presented by Charter Communications – Manchin not ready yet; Meadows texts unveiled MORE said at a briefing.



Read original article here

Who’s getting sick? Report sheds new light on breakthrough cases and vaccine protection against hospitalization

As Ontario tries to keep a resurgence of COVID-19 cases under control, new data from Public Health Ontario shows only nine fully vaccinated people under 60 have ended up in the ICU.

The report paints the most detailed picture yet of breakthrough cases — and who is getting very sick despite being fully vaccinated — showing that the majority of those who need hospital care are adults over the age of 60, with the highest proportion in their 80s.

Experts say the findings underscore that vaccines are working well to prevent infections and hospitalizations. But they also support opening up third doses of the COVID vaccine to more older adults, and highlight why masking and other public health measures are still critical at this stage of the pandemic to protect the most vulnerable.

“It’s clear that vaccines are working phenomenally well,” said Dr. Isaac Bogoch, an infectious disease expert and a former member of Ontario’s now disbanded vaccine task force.

“But if you look at all the breakthrough cases, there is a greater probability that the older age cohorts will have more serious infections.” Based on this and data from other parts of the world, “it would make sense to expand third dose eligibility to the 50-year-old age cohort and up.”

Third doses have been opened up widely in the U.S. and Israel, but in Ontario only a few groups qualify, including health-care workers, individuals 70 and up, people who got two doses of AstraZeneca or one dose of Johnson & Johnson, and First Nations, Inuit and Métis adults. You have to be 168 days past your second dose to get a third one. Immunocompromised people, transplant recipients, patients with hematological cancers, and seniors living in congregate settings, such as long-term-care homes, retirement homes and First Nations elder care lodges, are also eligible.

The Public Health Ontario report, which includes COVID vaccination and case data up until Nov. 14, shows there were only 17,596 breakthrough cases out of the 11.1 million individuals who have completed two doses of the vaccine. As of Nov. 14, there were just 40 cases following a third dose, the data shows.

“The take-home message is that the COVID-19 vaccines … are highly effective at protecting against infection, and particularly effective at protecting against serious outcomes, including hospitalization and death, from COVID-19,” Dr. Sarah Wilson, a public health physician at Public Health Ontario, said in an email to the Star.

As of Nov. 14, unvaccinated individuals made up 91 per cent of COVID cases in Ontario, with breakthrough infections accounting for 3.8 per cent of cases. Public Health Ontario defines a breakthrough case as “individuals who have received two doses of a COVID-19 vaccine and were infected more than two weeks after receiving their second dose,” Wilson said.

The report notes a similar trend was observed for COVID hospitalizations and deaths “with unvaccinated cases accounting for 90.9 per cent of hospitalizations and 90.2 per cent of deaths while breakthrough cases accounted for 2.7 per cent of hospitalizations and 3.3 per cent of deaths.” As of Nov. 14, 178 fully vaccinated individuals had died of a COVID infection.

While the data shows older adults are more at risk of hospitalization from a breakthrough infection — particularly those over the age of 80 — the rate of “hospitalizations was higher among unvaccinated individuals compared to fully vaccinated individuals.”

Wilson said the data makes it clear the risk of COVID infection is higher for those who are unvaccinated. For those 60 and older, the risk of being hospitalized with the virus was about 16 times higher for unvaccinated individuals compared to those who had two doses.

Dr. Zain Chagla, an associate professor at McMaster University, said only nine intensive care unit admissions in people under 60 is “pretty remarkable,” but the “opposite side of the coin though is those over 60 probably do require booster doses.”

Especially since global vaccine supply is still strained and there are people in some countries who still don’t have access to first and second doses, “you want to make sure (third doses) are used in people where they’re going to derive the most benefit.”

Lucy Gerardi, who turns 68 soon, would be first in line if third doses were opened up for her age group.

“You just want to have that extra sense of security,” said the retired biology teacher and Oakville resident. As of Tuesday, it has been 168 days since her second shot and she’s been calling around to public health officials trying to get more information about when she can get a third, to no avail.

“You’re just kind of in limbo,” Gerardi said.

“But I guess we should be thankful we at least have two shots, when there are people in the world that have none.”

Nearly 420,000 third doses have been administered in Ontario, according to Ministry of Health spokesperson Bill Campbell, up from 290,000 last week. These numbers will start being reported publicly soon. “Ontario’s plan is to gradually expand eligibility for a booster dose to all Ontarians over time,” he said in an emailed statement. For now, in line with National Advisory Committee on Immunization (NACI) recommendations, they are being offered to vulnerable populations, Campbell added.

While the Ontario data shows COVID vaccines work very well, they still do not offer complete protection, said Dr. Abdu Sharkawy, an infectious diseases specialist at University Health Network.

“The message that is distilled from this report should not be one of nihilism, that vaccines just don’t work well enough,” he said. “The vaccines work very well, but they have their limitations.”

That’s why maintaining public health measures, particularly masking and minimizing risks that come with crowded, poorly ventilated indoor spaces, is still critical, even with a highly immunized population, Sharkawy said.

“We have to maintain a sense of vigilance around those things that can prevent at-risk people from becoming sick. And that means preventing the possibility of breakthrough infection by not simply relying on the vaccines alone.”

Wilson said Public Health Ontario will be publishing further reports on breakthrough infections “that could be used to inform third dose rollout” and that researchers are looking at data on different age groups and the timing of infection after a second dose.



Read original article here